Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Delta sleep-inducing peptide (DSIP) is a research peptide studied for sleep regulation. In published human studies, doses have typically ranged from roughly 25 to 500 micrograms by injection, often before sleep. DSIP is not FDA-approved, dosing is not standardized, and any use should be guided by a licensed clinician after evaluation [1,2,3].
| Study-reported DSIP range | Route studied | Timing described in research | What it means for patients |
|---|---|---|---|
| About 25 micrograms | Injection, including intravenous or subcutaneous routes in older studies | Often studied near the sleep period | A low research dose reported in human sleep studies; not an FDA-approved or clinician-recommended dose for the reader [3,4]. |
| About 100 micrograms | Injection | Often before sleep or during monitored sleep protocols | A commonly cited research amount in older DSIP literature; response was variable and safety data were limited [2,3]. |
| About 250 micrograms | Injection | Usually described in relation to bedtime or sleep-lab monitoring | A mid-range research dose; no standard medical dosing chart exists because DSIP is not FDA-approved [4,8]. |
| About 500 micrograms | Injection | Studied in some human protocols before sleep | An upper range reported in older human research; this is not a dosing instruction and should not be used without licensed medical evaluation [3,4]. |
| Intranasal DSIP | Intranasal administration has been discussed in peptide-use settings, but robust FDA-reviewed human dosing data are lacking | Timing is not standardized | No FDA-approved intranasal DSIP product or dosing schedule exists [8,10]. |
What is DSIP (delta sleep-inducing peptide)?
DSIP means delta sleep-inducing peptide, a small peptide made of 9 amino acids. A peptide this size is also called a nonapeptide. DSIP was first described in the 1970s after researchers observed sleep-related electrical brain-wave changes in animal experiments [1].
DSIP is often marketed online as a “sleep peptide,” but that wording can be misleading. DSIP is not FDA-approved for insomnia, sleep quality, anxiety, recovery, longevity, or any other medical use. It is best understood as a research peptide classification, not a standard sleep medicine [8,10].
Because DSIP is not FDA-approved, there is no FDA-reviewed label, no approved dose, and no official patient dosing chart. Any discussion of DSIP dosing should be read as research history, not as instructions for use [8].
How is DSIP thought to work?
DSIP has been investigated for effects on sleep regulation, stress biology, and brain signaling, but its exact role in humans remains unclear. The strongest claim the evidence supports is that DSIP has been studied for sleep architecture, not that it reliably improves sleep for everyone [2,5].
Mechanism in sleep regulation
Sleep architecture means the pattern of sleep stages across the night. Older DSIP studies looked at delta waves, which are slow brain waves linked with deep or slow-wave sleep. This is why DSIP is connected with the phrase “delta sleep” [1,2].
Researchers have also studied DSIP-like material in the brain and body, but the peptide’s natural function is still debated. Some work suggests DSIP may interact with neuroendocrine systems, which are hormone-and-brain signaling pathways [5,6].
What the research actually shows
Human research on DSIP is small and older. Some studies reported changes in sleep measures, while others found limited or inconsistent effects. This mixed evidence is one reason DSIP has not become an FDA-approved sleep drug [2,3,4,5,8].
Possible benefits should be weighed with uncertainty. Side effects, drug interactions, and long-term risks are not well defined, especially for products sold outside regulated clinical settings [2,10].
What dose of DSIP has been used in studies?
DSIP doses in published human studies have generally been reported in the microgram range, with about 25 to 500 micrograms appearing in older sleep research. These study doses are not a recommendation, and DSIP is not FDA-approved for the uses being studied [3,4,8].
Reported dose ranges
Older human studies used small injection doses, often described around 25, 100, 250, or 500 micrograms. The studies were generally small, and methods varied. That makes it hard to turn the research into a standard dosing chart [2,3,4].
A key point: “used in a study” does not mean “safe or right for you.” Study participants were monitored under research conditions, and modern commercial products may differ in purity, sterility, storage, and labeling accuracy [3,4,10].
Route of administration
Most DSIP dosing references come from injection-based research. Subcutaneous injection means an injection under the skin. Intravenous injection means into a vein. These routes carry risks such as infection, irritation, dosing error, and product contamination if not handled through proper medical and pharmacy systems [3,4,10].
Intranasal administration is sometimes discussed in peptide communities, but there is no FDA-approved intranasal DSIP product and no FDA-reviewed intranasal dosing schedule. Absorption through the nose can vary from person to person [8,10].
Timing relative to sleep
In sleep-lab research, DSIP was often studied near the sleep period or before planned sleep monitoring. That timing was part of research design, not a general instruction to take DSIP before bed [3,4].
If a person has insomnia, sleep apnea symptoms, restless legs, shift-work sleep problems, depression, or medication-related sleep trouble, the safer first step is medical evaluation. These conditions can need different care than a peptide or supplement [11].
Is there a standard DSIP dosing chart?
No. DSIP does not have a standard FDA-approved dosing chart because it is not FDA-approved for any medical use. The chart below is a research-reference summary only, based on doses reported in older human studies [3,4,8].
| Reference range seen in research | How it was commonly studied | Evidence strength | Important safety note |
|---|---|---|---|
| 25 mcg | Injection in monitored human sleep research | Very limited; older small studies | Not a personal starting dose. DSIP is not FDA-approved [3,8]. |
| 100 mcg | Injection before or during sleep-study protocols | Limited; mixed sleep findings | Effects and risks are not well established [2,3]. |
| 250 mcg | Injection in some older DSIP protocols | Limited; not enough for an approved label | No FDA-reviewed dosing schedule exists [4,8]. |
| 500 mcg | Injection in some older human research | Limited; upper range often cited from research literature | Higher research exposure does not mean safer or more effective [3,4]. |
| Intranasal dosing | Discussed outside FDA-approved labeling | Insufficient for a standard chart | No FDA-approved intranasal DSIP product or dose exists [8,10]. |
How to read this chart
Read the chart as a map of what researchers have reported, not what you should use. A licensed clinician would consider sleep diagnosis, medications, medical history, pregnancy status, substance use, and product legality before discussing any peptide [10,11].
The absence of a standard chart matters. FDA-approved medicines come with reviewed labeling that includes dose, route, contraindications, warnings, and adverse reactions. DSIP does not have that FDA-reviewed label [8].
What are the side effects and risks of DSIP?
DSIP side effects are not well characterized because human studies are small and older. The main safety concern is uncertainty: there is not enough high-quality human data to define rare risks, long-term effects, pregnancy risks, or interactions with sedatives and other sleep medicines [2,3,4].
- Injection-site pain, redness, bruising, or infection can occur with injected products in general, especially if sterility is poor [10].
- Daytime sleepiness or next-day grogginess is possible with any product that affects sleep, though DSIP-specific rates are not well established [2,5].
- People taking alcohol, benzodiazepines, opioids, sedating antihistamines, sleep medicines, or psychiatric medications should be especially cautious and speak with a clinician [11].
- People who are pregnant, trying to become pregnant, breastfeeding, immunocompromised, or living with serious medical conditions should not use research peptides without specialist guidance [10,11].
- Products sold online as “research peptides” may not have FDA review for identity, purity, sterility, or manufacturing quality [10].
Because benefits are uncertain, safety should not be treated as a small footnote. If a sleep problem is new, severe, or linked with snoring, gasping, chest pain, mood changes, or use of sedating drugs, a medical workup is more useful than trying to self-dose a peptide [11].
Is DSIP legal and FDA-approved?
DSIP is not FDA-approved for insomnia, sleep quality, recovery, longevity, or any other indication. It does not have an FDA-approved drug label, and it is not listed as an approved prescription drug in FDA drug-approval resources [8].
A 503A compounding pharmacy is a state-licensed pharmacy that can prepare certain medications for an individual patient when there is a valid prescription and legal basis to compound. Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or manufacturing quality [9,10].
How do people obtain DSIP through a licensed clinician?
DSIP should not be obtained from unverified online sellers or used without medical guidance. A licensed telehealth prescriber can review sleep symptoms, current medicines, medical history, and whether any legal, evidence-based option is appropriate; Chia is one telehealth option for clinician-reviewed care, while DSIP itself remains not FDA-approved [8,10,11].
For sleep concerns, clinicians may first look for common causes such as sleep apnea, anxiety, depression, alcohol use, caffeine timing, thyroid disease, restless legs, or medication effects. Treating the cause is often safer than focusing only on a sleep-promoting compound [11].
DSIP vs other sleep-related peptides and supplements
DSIP is different from common sleep supplements because it is a research peptide, not an over-the-counter dietary supplement with broad consumer use. It is also different from FDA-approved sleep medicines, which have reviewed labels, warnings, contraindications, and dose instructions [8,11].
| Option | What it is | FDA status | Main caveat |
|---|---|---|---|
| DSIP | Delta sleep-inducing peptide; a nonapeptide studied for sleep architecture | Not FDA-approved for any use | No standard dose, limited human safety data, mixed sleep evidence [2,8]. |
| Sermorelin | Growth hormone–releasing hormone analog studied for growth hormone pathways | FDA-approved products have been discontinued; compounded use depends on legal and clinical context | Not a sleep drug; may affect hormone pathways and needs clinician oversight [10]. |
| Melatonin | Hormone sold as a dietary supplement in the United States | Not FDA-approved as a drug for insomnia in the U.S. | Product strength can vary; timing and dose should be discussed with a clinician when sleep problems are ongoing [11,12]. |
| Prescription insomnia medicines | FDA-approved drugs for specific sleep indications | FDA-approved when used according to their labels | Can cause next-day impairment, dependence risk, complex sleep behaviors, or drug interactions depending on the medicine [11]. |
| CBT-I | Cognitive behavioral therapy for insomnia | Non-drug therapy recommended in clinical guidelines | Takes practice and access to trained care, but is a first-line option for chronic insomnia [11]. |
For chronic insomnia, professional guidelines often recommend cognitive behavioral therapy for insomnia, called CBT-I, as a first-line approach. It can address sleep habits, worry around sleep, and the body’s sleep-wake rhythm without adding an unapproved peptide [11].
DSIP, or delta sleep-inducing peptide, is a nine–amino acid research peptide first studied for sleep-related brain-wave changes. It is not FDA-approved for sleep, insomnia, recovery, or longevity [1,8].
There is no approved or standard DSIP dosage. Older human studies reported injection doses roughly from 25 to 500 micrograms, but those are research ranges, not instructions for personal use [3,4,8].
Some older sleep studies gave DSIP near the sleep period or before monitored sleep. That timing was part of research design and should not be treated as a bedtime dosing rule [3,4].
Intranasal DSIP is discussed in some peptide-use settings, but there is no FDA-approved intranasal DSIP product and no FDA-reviewed intranasal dosing schedule. Absorption and safety are not well established [8,10].
DSIP safety is not well established. Human studies are small and older, and there is not enough evidence to define long-term risks, rare side effects, pregnancy risks, or interactions with sedating medications [2,3,11].
No. DSIP is not FDA-approved for any medical use. Compounded drugs are also not FDA-approved and are not reviewed by FDA for safety, effectiveness, or manufacturing quality [8,10].
Yes. AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health. A prescription is not guaranteed, and DSIP is not FDA-approved; a licensed clinician must decide what, if anything, is appropriate.
Start with a licensed clinician evaluation, especially if you snore, gasp during sleep, feel very sleepy during the day, take sedating medications, or have mood symptoms. Many sleep problems have treatable causes that should be checked first [11].
References
- 1.Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram sleep-inducing peptide. Proceedings of the National Academy of Sciences of the United States of America, 1977.
- 2.Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neuroscience & Biobehavioral Reviews, 1986.
- 3.Schneider-Helmert D, Schoenenberger GA, Feinberg I. Effects of delta-sleep-inducing peptide on sleep in man. Sleep, 1981.
- 4.Schneider-Helmert D. Treatment of chronic pronounced insomnia by delta-sleep-inducing peptide. European Neurology, 1981.
- 5.Pollmächer T, Mullington J, Korth C, Schreiber W, Hermann D, Holsboer F. Influence of delta-sleep-inducing peptide on sleep and endocrine secretion in humans. Neuropsychobiology, 1987.
- 6.Charnay Y, Bouras C, Vallet PG, Constantinidis J. Immunocytochemical localization of delta sleep-inducing peptide-like material in the human brain. Neuroscience Letters, 1989.
- 7.Banks WA, Kastin AJ. Peptide transport systems for opiates across the blood-brain barrier. American Journal of Physiology, 1990.
- 8.U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs database. U.S. Food and Drug Administration, 2026.
- 9.U.S. Food and Drug Administration. Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry. U.S. Food and Drug Administration, 2018.
- 10.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2024.
- 11.Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine, 2017.
- 12.Erland LAE, Saxena PK. Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content. Journal of Clinical Sleep Medicine, 2017.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
